Ethan Billings, Chief Advisor and Analyst at TD Securities in Washington, provides tailored trading strategies for a select group of high-net-worth clients. Specializing in the biotech sector, he regularly shares in-depth research reports highlighting high-quality investment opportunities. In addition, he has established a dedicated WhatsApp group for strategy discussions, where members receive timely and precise buy/sell recommendations.
Below is a summary of some of the key biotech stocks recently featured in his reports:
1.Forte Biosciences (FBRX)
Investment Highlights: FBRX is focused on microbiome-based therapies, with its lead candidate FB-401, a live biotherapeutic targeting atopic dermatitis (eczema). Early clinical data has shown good safety and preliminary efficacy. The company is targeting the large immuno-dermatology market, and if future trials are successful, it could become a disruptive treatment in this space.
Future Outlook: Key data expected in 2024–2025 will be crucial in determining the commercial viability of FB-401. A positive outcome could lead to partnerships with major pharmaceutical companies or a potential acquisition.
Financials: Still in the clinical stage, the company depends on cash reserves to fund further trials. It currently has no revenue but has a small market cap and high upside potential.
2.REGENXBIO (RGNX)
Investment Highlights: RGNX is a leader in AAV gene therapy, supported by its proprietary NAV® platform, which is licensed to major pharma players like Novartis and Pfizer, generating strong royalty income. Its key programs include RGX-121 (MPS II) and RGX-202 (DMD), both targeting rare diseases with defined market opportunities.
Future Outlook: Clinical results expected between 2025 and 2026 will determine the competitiveness of these gene therapies. Successful outcomes could lead to multi-billion-dollar market potential.
Financials: The company generates steady royalty revenue but has high R&D costs and depends on financing or milestone payments from partners to support operations.
3.AnaptysBio (ANAB)
Investment Highlights: ANAB is focused on immune-inflammatory diseases. Its lead candidate, imsidolimab (an anti-IL-36R antibody), is being developed for generalized pustular psoriasis (GPP), with strong clinical data suggesting it could be a best-in-class treatment. Another program, PD-1 agonist ANB030, also shows promise in atopic dermatitis.
Future Outlook: If approved for GPP in 2024–2025, the drug could become a blockbuster and be expanded to treat other inflammatory conditions.
Financials: The company has enough cash to operate through 2026. Revenue is expected to grow significantly upon commercialization.
4.Arcutis Biotherapeutics (ARQT)
Investment Highlights: ARQT is a rising player in dermatology. Its lead product, ZORYVE® (roflumilast foam), is approved for plaque psoriasis and being expanded into seborrheic dermatitis and eczema—markets with strong potential. The topical delivery format offers advantages over injectables, improving patient adherence.
Future Outlook: Approvals for additional indications in 2024–2025 are expected to drive sales growth, and the company could be an attractive acquisition target for larger players.
Financials: Revenues began ramping up in 2024, with the company expected to approach breakeven in 2025.
5.Krystal Biotech (KRYS)
Investment Highlights: KRYS is a leader in genetic therapies for dermatology. Its product, Vyjuvek
, is the first FDA-approved gene therapy for dystrophic epidermolysis bullosa (EB), priced at over $1M per year, giving it strong market exclusivity. The pipeline also includes therapies for respiratory and dermatologic conditions.
Future Outlook: After 2025, the company plans to expand Vyjuvek globally and advance its gene therapy for TGM1-deficient ichthyosis.
Financials: Commercial revenue began accelerating in 2023. The company has strong cash flow and could achieve profitability soon.
6.Cara Therapeutics (CARA)
Investment Highlights: CARA is focused on treating chronic pruritus. Its flagship product, KORSUVA (difelikefalin), is the first approved therapy for chronic kidney disease-associated pruritus (CKD-aP), with significant market potential. An oral formulation is in development for broader indications such as atopic dermatitis and liver-related pruritus.
Future Outlook: If the data for oral KORSUVA in 2025 is positive, the drug could become a major revenue driver.
Financials: Currently relies on partnership income (from Vifor Pharma). If self-commercialization efforts succeed after 2025, profitability is likely to improve.
7.Verrica Pharmaceuticals (VRCA)
Investment Highlights: VRCA is focused on viral skin infections. Its product, YCANTH, is the first FDA-approved treatment for molluscum contagiosum, filling a significant unmet need. The addressable market exceeds $500M annually, with minimal competition.
Future Outlook: Sales are expected to scale up in 2024–2025, with potential expansion into conditions like epidermodysplasia verruciformis.
Financials: Commercial revenue growth began in 2024. If sales outperform expectations, the company may quickly reach profitability.
Industry Trends & Investment Strategy
– Gene therapy (RGNX, KRYS) and microbiome-based therapies (FBRX) represent next-generation innovation. These offer str
Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.
